Meeting
2020 ASCO Virtual Scientific Program
Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma (Trial in Progress).
Authors
Judah D. Friedman
University Hospitals Seidman Cancer Center, Cleveland, OH
Judah D. Friedman , Hun Ju Lee , Linda Ho , Ian Flinn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03646123
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS8068)
DOI
10.1200/JCO.2020.38.15_suppl.TPS8068
Abstract #
TPS8068
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.
First Author: David J. Straus
Poster
2023 ASCO Annual Meeting
Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.
First Author: Jackson Bowers
Poster
2022 ASCO Annual Meeting
Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study.
First Author: Jane N. Winter
Poster
2021 ASCO Annual Meeting
Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.
First Author: Howland E. Crosswell